{"id":"bromfenac-ophthalmic-solution-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Stinging or burning upon instillation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"246e2110-6a2d-4e22-8e37-72d80796b9af","title":"BROMFENAC OPHTHALMIC SOLUTION (BROMFENAC SODIUM) SOLUTION/ DROPS [BAUSCH & LOMB AMERICAS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking COX-1 and COX-2 enzymes, bromfenac decreases production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. The ophthalmic solution formulation allows direct delivery to the anterior segment.","oneSentence":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:54.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following cataract surgery"},{"name":"Ocular itching associated with allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT01212471","phase":"PHASE3","title":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bromfenac Ophthalmic Solution B","genericName":"Bromfenac Ophthalmic Solution B","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. Used for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}